CRISPR Therapeutics Funding: How Much Did They Raise & Key Investors

How Much Did CRISPR Therapeutics Raise?
Funding & Key Investors

CRISPR Therapeutics has solidified its position as a leader in the biotechnology sector, securing a significant capital injection to advance its proprietary gene-editing platform. The company has successfully raised a total of $56M to date, with the most recent strategic investment totaling $56M. This influx of financing underscores the market confidence in the firm's ability to translate complex molecular science into viable clinical therapies for patients suffering from severe genetic disorders.

The capital allocation strategy reflects a commitment to scaling research and development operations, ensuring that the company remains at the forefront of the rapidly evolving genomic medicine landscape. By leveraging this investment, CRISPR Therapeutics is well-positioned to navigate the rigorous regulatory pathways required for bringing gene-based medications to market.

What is CRISPR Therapeutics?

CRISPR Therapeutics

Manufacturing

Pharmaceuticals

Business Services

Founded in 2013 and headquartered in Zug, Switzerland, CRISPR Therapeutics is a pioneering biopharmaceutical company dedicated to the development of transformative gene-based medicines. The firm utilizes the CRISPR/Cas9 platform to target diseases at the molecular level, focusing on high-unmet-need conditions such as hemoglobinopathies and immuno-oncology. By operating at the intersection of advanced genetic engineering and clinical medicine, the company has established a robust pipeline that aims to provide curative solutions rather than mere symptom management. Its market position is defined by its intellectual property portfolio and its strategic focus on precision medicine, which continues to attract significant interest from institutional investors and industry partners alike.

How much funding has CRISPR Therapeutics raised?

CRISPR Therapeutics has raised a total of $56M across 1 funding round:

2016

Stock Offering

$56M

Stock Issuance/Offering (2016): $56M, investors not publicly disclosed

Key Investors in CRISPR Therapeutics

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for CRISPR Therapeutics?

Looking ahead, the strategic deployment of the $56M will likely focus on accelerating clinical trial milestones and expanding the company's manufacturing capabilities. As the firm transitions from a research-heavy entity to a clinical-stage powerhouse, the focus will shift toward demonstrating long-term safety and efficacy in human trials. The company is expected to prioritize the advancement of its lead candidates through Phase II and Phase III studies, while simultaneously exploring new therapeutic indications for its gene-editing technology. This growth trajectory suggests a long-term commitment to establishing a sustainable commercial presence in the global healthcare market, potentially setting the stage for future partnerships or licensing agreements that could further validate its technological platform.

See full CRISPR Therapeutics company page

See More Financial Insights